Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

BACKGROUND & OBJECTIVE: “Anti-angiogenetic drugs plus chemotherapy” (anti-angio-chemo) and “immune checkpoint inhibitors plus chemotherapy” (ICI-chemo) are superior to traditional chemotherapy in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). However, in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Lan-Lan, Gan, Jia-Di, Huang, Yi-Hua, Liao, Jun, Zhuang, Wei-Tao, Ali, Wael-Abdullah-Sultan, Hong, Shao-Dong, Zhang, Li, Fang, Wen-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862794/
https://www.ncbi.nlm.nih.gov/pubmed/36670414
http://dx.doi.org/10.1186/s12885-022-10446-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862794/
https://www.ncbi.nlm.nih.gov/pubmed/36670414
http://dx.doi.org/10.1186/s12885-022-10446-1

Ejemplares similares